Drugs / Endoxifen

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT03317405 Oct 2018 → Feb 2021 overdue ductal breast carcinoma in situ, lobular breast carcinoma in situ National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT01327781 Mar 2011 → Mar 2017 overdue HER2 positive breast carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT01273168 Mar 2011 → Jun 2020 desmoid tumor, female reproductive system neoplasm, hormone receptor-positive breast cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 26 trials
Phase 2 NCT06075953 Feb 2024 → Nov 2028 expected ductal breast carcinoma in situ QuantumLeap Healthcare Collaborative Recruiting No outcome recorded
Phase 2 NCT05607004 Feb 2023 → Nov 2026 expected Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive breast carcinoma Atossa Therapeutics, Inc. Active not recruiting No outcome recorded
Phase 2 NCT05068388 Dec 2021 → Jun 2024 female breast upper-inner quadrant cancer Atossa Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT03931928 Sep 2019 → May 2021 ductal breast carcinoma in situ Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) Completed No outcome recorded
Phase 2 NCT02311933 May 2015 → Nov 2020 overdue breast carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 2 NCT01042379 Mar 2010 → Dec 2030 expected HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 QuantumLeap Healthcare Collaborative Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT06608641 Mar 2024 → Jun 2025 overdue bipolar I disorder Jina Pharmaceuticals Inc. Active not recruiting No outcome recorded
Phase 3 NCT04315792 Aug 2020 → Jan 2021 bipolar I disorder Jina Pharmaceuticals Inc. Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04616430 Comparator Apr → Sep 2018 breast disorder Atossa Therapeutics, Inc. Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as endoxifen “The experimental drug Z-Endoxifen HCl (endoxifen) is related to tamoxifen” NCT01273168
5

NCT03317405

NCT04315792

NCT04616430

NCT06608641

NCT02311933

Known as 4-hydroxy-n-desmethyltamoxifen ChEMBL registry synonym — accepted as the source's own label CHEMBL1093458
Known as ENX “endoxifen hydrochloride (endoxifen [ENX]) gel” NCT03317405
Known as N-desmethyl-4-hydroxytamoxifen ChEMBL registry synonym — accepted as the source's own label CHEMBL1093458
Known as NSC-749798 ChEMBL registry synonym — accepted as the source's own label CHEMBL1093458
Known as Z endoxifen HCl “The experimental drug Z-Endoxifen HCl (endoxifen) is related to tamoxifen” NCT01273168
Known as Z-endoxifen “Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25...” NCT03931928
10

“BACKGROUND: (Z)-endoxifen is the tamoxifen metabolite that possesses the highest affinity to the estrogen receptor and is evolving as an alternative to tamoxifen.” PMID 42070780 Apr 2026

“(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen.” NCT06075953

“To describe the safety profile of Z-endoxifen (Z-endoxifen hydrochloride) at each of the doses examined.” NCT01327781

“The experimental drug Z-Endoxifen HCl (endoxifen) is related to tamoxifen” NCT01273168

NCT01273168

NCT05068388

NCT03931928

NCT01042379

NCT06075953

NCT05607004

Action Inhibit “lowering the amount of estrogen the body makes” NCT02311933
Modality Small molecule CHEMBL1093458
Route Oral “Z-endoxifen: 10 mg QD, p.o.” NCT01042379